Prescribing antitumor necrosis factor drugs to patients with heart failure

Arch Intern Med. 2005 Jan 10;165(1):118-9. doi: 10.1001/archinte.165.1.118-b.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antirheumatic Agents / administration & dosage
  • Antirheumatic Agents / adverse effects
  • Etanercept
  • Heart Failure / complications*
  • Heart Failure / drug therapy
  • Humans
  • Immunoglobulin G / administration & dosage
  • Immunoglobulin G / adverse effects
  • Infliximab
  • Randomized Controlled Trials as Topic
  • Receptors, Tumor Necrosis Factor / administration & dosage
  • Risk Factors
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Etanercept